Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.
about
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.Drug-Target Kinetics in Drug Discovery.Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.
P2860
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Btk-specific inhibition blocks ...... n IFNα-driven lupus nephritis.
@en
Btk-specific inhibition blocks ...... n IFNα-driven lupus nephritis.
@nl
type
label
Btk-specific inhibition blocks ...... n IFNα-driven lupus nephritis.
@en
Btk-specific inhibition blocks ...... n IFNα-driven lupus nephritis.
@nl
prefLabel
Btk-specific inhibition blocks ...... n IFNα-driven lupus nephritis.
@en
Btk-specific inhibition blocks ...... n IFNα-driven lupus nephritis.
@nl
P2093
P2860
P1433
P1476
Btk-specific inhibition blocks ...... in IFNα-driven lupus nephritis
@en
P2093
Adam Johnson
Allen Nguyen
Arna Katewa
Cary D Austin
Chungkee Poon
Harvey Wong
Jacob Zhi Chen
Jason DeVoss
Jianyong Wang
P2860
P304
P356
10.1172/JCI.INSIGHT.90111
P577
2017-04-06T00:00:00Z